Preclinical Alzheimer disease—the challenges ahead

被引：0
作者：
Reisa A. Sperling
Jason Karlawish
Keith A. Johnson
机构：
[1] Center for Alzheimer Research and Treatment,Departments of Neurology
[2] Brigham and Women's Hospital and Massachusetts General Hospital,Departments of Medicine and Medical Ethics and Health Policy
[3] University of Pennsylvania,Departments of Radiology and Neurology
[4] Massachusetts General Hospital,undefined
来源：
Nature Reviews Neurology | 2013年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pathological changes underlying Alzheimer disease (AD) begin more than 10 years before clinical presentation, and the need for early therapeutic intervention is becoming increasingly recognized. Reisa Sperling and colleagues consider challenges to such an approach—including the difficulty of defining preclinical AD, and ethical issues associated with disclosing information on AD biomarker status to healthy individuals—and discuss possible ways to overcome these hurdles.
引用
收藏
页码：54 / 58
页数：4
相关论文
共 50 条
  • [41] Trial of Solanezumab in Preclinical Alzheimer's Disease
    Sperling, Reisa A.
    Donohue, Michael C.
    Raman, Rema
    Rafii, Michael S.
    Johnson, Keith
    Masters, Colin L.
    van Dyck, Christopher H.
    Iwatsubo, Takeshi
    Marshall, Gad A.
    Yaari, Roy
    Mancini, Michele
    Holdridge, Karen C.
    Case, Michael
    Sims, John R.
    Aisen, Paul S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (12) : 1096 - 1107
  • [42] Aging, preclinical Alzheimer disease, and early detection
    Price, JL
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2003, 17 : S60 - S62
  • [43] Personality Change in the Preclinical Phase of Alzheimer Disease
    Terracciano, Antonio
    An, Yang
    Sutin, Angelina R.
    Thambisetty, Madhav
    Resnick, Susan M.
    JAMA PSYCHIATRY, 2017, 74 (12) : 1259 - 1265
  • [44] Onset of Preclinical Alzheimer Disease in Monozygotic Twins
    Konijnenberg, Elles
    Tomassen, Jori
    den Braber, Anouk
    ten Kate, Mara
    Yaqub, Maqsood
    Mulder, Sandra D.
    Nivard, Michel G.
    Vanderstichele, Hugo
    Lammertsma, Adriaan A.
    Teunissen, Charlotte E.
    van Berckel, Bart N. M.
    Boomsma, Dorret, I
    Scheltens, Philip
    Tijms, Betty M.
    Visser, Pieter Jelle
    ANNALS OF NEUROLOGY, 2021, 89 (05) : 987 - 1000
  • [45] The biomarker signature of preclinical Alzheimer's disease
    Molinuevo, J. L.
    JOURNAL OF NEUROLOGY, 2013, 260 : S9 - S10
  • [46] Polygenic Hazard Scores in Preclinical Alzheimer Disease
    Tan, Chin Hong
    Hyman, Bradley T.
    Tan, Jacinth J. X.
    Hess, Christopher P.
    Dillon, William P.
    Schellenberg, Gerard D.
    Besser, Lilah M.
    Kukull, Walter A.
    Kauppi, Karolina
    McEvoy, Linda K.
    Andreassen, Ole A.
    Dale, Anders M.
    Fan, Chun Chieh
    Desikan, Rahul S.
    ANNALS OF NEUROLOGY, 2017, 82 (03) : 484 - 488
  • [47] Sleep Disruption and Risk of Preclinical Alzheimer Disease
    Ju, Yo-el
    Duntley, Stephen
    Fagan, Anne
    Morris, John
    Holtzman, David
    NEUROLOGY, 2012, 78
  • [48] Pathology of clinical and preclinical Alzheimer’s disease
    Dietmar Rudolf Thal
    Christine von Arnim
    W. Sue T. Griffin
    Haruyasu Yamaguchi
    Robert E. Mrak
    Johannes Attems
    Ajeet Rijal Upadhaya
    European Archives of Psychiatry and Clinical Neuroscience, 2013, 263 : 137 - 145
  • [49] Early-stage and preclinical Alzheimer disease
    Morris, JC
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2005, 19 (03) : 163 - 165
  • [50] Neuroimaging to predict preclinical Alzheimer's disease
    Kumari, V
    Mitterschiffthaler, MT
    Sharma, T
    HOSPITAL MEDICINE, 2002, 63 (06): : 341 - 345
12345